BackChromadex Overview

Chromadex Receivables

Latest receivables for CDXC: $8.6M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$8.58M
↓ 11.14% YoYΔ $-1.08M vs prior year quarter

Peer trimmed avg / median

Loading

Chromadex Receivables History

Loading

Chromadex vs. peers: Receivables Comparison

Loading

Chromadex Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Chromadex (CDXC) FAQ

Chromadex (CDXC) currently reports a receivables of $8.6M as of June 2026. That compares with $9.7M in the prior-year period — down 11.1% year over year. Use the charts on this page to explore Chromadex's receivables history and peer comparisons.

Chromadex's receivables decreased from $9.7M to $8.6M — a 11.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chromadex reported $8.6M in receivables as of June 2026. That compares with $9.7M in the prior-year period — down 11.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $8.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chromadex, and consider following CDXC for alerts when major investors trade the stock.

Chromadex is classified in the Healthcare sector. On receivables, it currently shows $8.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDXC with unrelated industries.